Tag: Ontario Brain Institute

Drug Candidate, CQ-001 (cannabidiol “CBD” + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.   TORONTO, ON / iCrowdNewswire / December 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” […]